November 22, 2016 - By Richard Conner · 0 Comments
The stock of Xencor Incorporated (NASDAQ:XNCR) registered an increase of 3.38% in short interest. XNCR’s total short interest was 2.15 million shares in November as published by FINRA. Its up 3.38% from 2.08M shares, reported previously. With 226,100 shares average volume, it will take short sellers 10 days to cover their XNCR’s short positions. The short interest to Xencor Incorporated’s float is 7.06%. The stock closed at $26.8 during the last session. It is down 89.40% since April 20, 2016 and is uptrending. It has outperformed by 84.84% the S&P500.
Xencor, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $1.10 billion. The Firm is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has a 27.71 P/E ratio. The Company’s segment is related to the development of pharmaceutical products.
Insitutional Activity: The institutional sentiment increased to 1.86 in Q2 2016. Its up 0.22, from 1.64 in 2016Q1. The ratio improved, as 10 funds sold all Xencor Inc shares owned while 23 reduced positions. 13 funds bought stakes while 41 increased positions. They now own 27.63 million shares or 4.30% less from 28.87 million shares in 2016Q1.
Schwab Charles Inv Management last reported 0% of its portfolio in the stock. Dekabank Deutsche Girozentrale has invested 0% of its portfolio in Xencor Inc (NASDAQ:XNCR). Metropolitan Life Ny reported 24,320 shares or 0% of all its holdings. Price T Rowe Md last reported 575,316 shares in the company. Blackrock Gru Incorporated Limited accumulated 6,824 shares or 0% of the stock. Moreover, Equitec Specialists Limited Liability Company has 0.02% invested in Xencor Inc (NASDAQ:XNCR) for 5,489 shares. Geode Capital Mgmt Ltd Liability holds 0% or 236,224 shares in its portfolio. Blackrock Advisors has invested 0% of its portfolio in Xencor Inc (NASDAQ:XNCR). Eventide Asset Lc last reported 0.4% of its portfolio in the stock. Arrowpoint Asset Mngmt Limited Liability holds 225,002 shares or 0.09% of its portfolio. Vanguard Grp Inc reported 1.34 million shares or 0% of all its holdings. Gsa Cap Partners Limited Liability Partnership accumulated 26,330 shares or 0.03% of the stock. Pnc Fincl Ser Group Incorporated owns 66,126 shares or 0% of their US portfolio. Spark Inv Management Ltd Liability Com holds 0.31% or 174,700 shares in its portfolio. Eam Investors Limited has invested 0.19% of its portfolio in Xencor Inc (NASDAQ:XNCR).
Insider Transactions: Since May 24, 2016, the stock had 0 insider purchases, and 17 selling transactions for $7.64 million net activity. Baracchini Edgardo Jr had sold 1,250 shares worth $18,875 on Tuesday, June 28. Another trade for 45,886 shares valued at $1.01M was made by Dahiyat Bassil I on Tuesday, August 16. STAFFORD JOHN S III sold $2.10M worth of stock. Foster Paul A had sold 5,000 shares worth $100,050 on Wednesday, August 3. $77,074 worth of shares were sold by CARTER BRUCE L A on Thursday, August 11. The insider Desjarlais John R sold $354,065.
Out of 5 analysts covering Xencor (NASDAQ:XNCR), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. $29 is the highest target while $18 is the lowest. The $22.33 average target is -16.68% below today’s ($26.8) stock price. Xencor has been the topic of 7 analyst reports since August 5, 2015 according to StockzIntelligence Inc. As per Tuesday, October 4, the company rating was initiated by Piper Jaffray. Leerink Swann maintained it with “Outperform” rating and $25 target price in Thursday, September 17 report. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, March 8 report. The firm has “Hold” rating given on Saturday, August 8 by Zacks. The company was upgraded on Friday, September 4 by Zacks. Canaccord Genuity initiated the shares of XNCR in a report on Tuesday, December 22 with “Buy” rating. MLV maintained the shares of XNCR in a report on Wednesday, August 5 with “Buy” rating.
Xencor, Inc., incorporated on June 8, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. The Company’s segment is related to the development of pharmaceutical products. The Firm uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. The Company’s clinical stage product candidates include XmAb5871, which is being developed for autoimmune disease, and XmAb7195, which is being developed for asthma and allergic diseases. The Company’s oncology product candidates are in preclinical stage, which include XmAb14045 for the treatment of acute myeloid leukemia (AML) and XmAb13676 for B-cell malignancy. In addition to its compounds in clinical development, the Company uses its XmAb technology to create antibody compounds which are licensed to other pharmaceutical and biotechnology companies for further development, which include XmAb5574/MOR208 (MOR208), an antibody drug candidate, and XmAb13551, a bispecific CD38 x CD3 preclinical candidate.
More notable recent Xencor Inc (NASDAQ:XNCR) news were published by: Fool.com which released: “This Caused Xencor Inc.’s Stock to Jump 11.6% in August” on September 10, 2016, also Fool.com with their article: “Why Xencor Inc’s Shares Are Skyrocketing Today” published on June 28, 2016, Prnewswire.com published: “Xencor Presents Preclinical Data on XmAb20717 Dual Checkpoint Blockade and …” on November 11, 2016. More interesting news about Xencor Inc (NASDAQ:XNCR) were released by: Prnewswire.com and their article: “Xencor to Host Third Quarter 2016 Financial Results Webcast and Conference …” published on October 26, 2016 as well as Prnewswire.com‘s news article titled: “Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of …” with publication date: November 13, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Richard Conner